Neuronetics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Neuronetics wird ein Gewinn- und Umsatzwachstum von 30.9% bzw. 13.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 34.9% pro Jahr wachsen soll.

Wichtige Informationen

30.9%

Wachstumsrate der Gewinne

34.9%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.6%
Wachstumsrate der Einnahmen	13.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	07 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 09

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet

May 24

The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 09

Neuronetics: Reality Set In

May 09

Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower

May 08

Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?

May 01

Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely

Mar 17

Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression

Aug 29

Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance

Aug 02

Neuronetics stock soars 30% as FDA clears NeuroStar system for anxious depression

Jul 19

Is Neuronetics (NASDAQ:STIM) A Risky Investment?

Jun 08

Is Neuronetics (NASDAQ:STIM) Weighed On By Its Debt Load?

Jan 19

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:STIM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	104	-14	N/A	N/A	2
12/31/2025	90	-20	N/A	N/A	4
12/31/2024	79	-28	N/A	N/A	4
3/31/2024	73	-28	-31	-29	N/A
12/31/2023	71	-30	-34	-32	N/A
9/30/2023	69	-33	-39	-37	N/A
6/30/2023	68	-31	-36	-34	N/A
3/31/2023	67	-37	-36	-34	N/A
12/31/2022	65	-37	-34	-31	N/A
9/30/2022	62	-37	-36	-32	N/A
6/30/2022	59	-37	-37	-34	N/A
3/31/2022	57	-34	-34	-31	N/A
12/31/2021	55	-31	-30	-28	N/A
9/30/2021	56	-27	-27	-25	N/A
6/30/2021	55	-22	-22	-20	N/A
3/31/2021	50	-23	-25	-24	N/A
12/31/2020	49	-27	-29	-28	N/A
9/30/2020	51	-31	-34	-33	N/A
6/30/2020	55	-35	-38	-37	N/A
3/31/2020	61	-34	-35	-35	N/A
12/31/2019	63	-29	-31	-30	N/A
9/30/2019	61	-28	-27	-26	N/A
6/30/2019	59	-26	-25	-24	N/A
3/31/2019	55	-26	-23	-22	N/A
12/31/2018	53	-24	-22	-21	N/A
9/30/2018	49	-23	-19	-18	N/A
6/30/2018	46	-22	-16	-15	N/A
3/31/2018	43	-17	-14	-13	N/A
12/31/2017	40	-16	N/A	-11	N/A
12/31/2016	34	-11	N/A	-9	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: STIM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: STIM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: STIM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: STIMDie Einnahmen des Unternehmens (13.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: STIMDie Einnahmen des Unternehmens (13.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von STIM in 3 Jahren voraussichtlich hoch sein wird

Neuronetics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024

Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023

Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Consensus EPS estimates upgraded to US$1.15 loss

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet

Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents

The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Neuronetics: Reality Set In

Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower

Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?

Neuronetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation

Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely

Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Full year 2023 earnings released: US$1.05 loss per share (vs US$1.38 loss in FY 2022)

Executive VP notifies of intention to sell stock

President recently sold US$71k worth of stock

President notifies of intention to sell stock

Neuronetics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Neuronetics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Executive VP recently sold US$53k worth of stock

Executive VP notifies of intention to sell stock

Executive VP recently sold US$52k worth of stock

Neuronetics Launches Latest Evolution in Its Trakstar® Patient Data Management System

Executive VP notifies of intention to sell stock

Neuronetics: Modest Improvements Are Not Enough

President recently sold US$60k worth of stock

Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023

Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward

Neuronetics Receives 510(K) Clearance for Neurosite Coil Placement Accessory

Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan

New minor risk - Share price stability

Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Neuronetics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Neuronetics, Inc. Announces the Launch of the NeuroStar Voices Portal

Consensus EPS estimates upgraded to US$1.15 loss

Neuronetics, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations

Neuronetics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Neuronetics, Inc Announces Expanded TMS Therapy Access Through Aetna® Health Plans

Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story

Neuronetics Receives 510(K) Clearance for Ocd Mt Cap for Neurostar Advanced Therapy

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2023

Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?

Executive VP recently sold US$58k worth of stock

Executive VP notifies of intention to sell stock

Price target decreased by 10% to US$8.67

President recently sold US$214k worth of stock

President notifies of intention to sell stock

Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer

High number of new directors

Neuronetics, Inc. Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar(R) Advanced Therapy for Mental Health

Neuronetics, Inc. Revised Revenue Guidance for the Fourth Quarter and Full Year of 2022

Neuronetics, Inc. Appoints Joseph H. Capper to Its Board of Directors and as Member of the Audit Committee, Effective January 1, 2023

Consensus estimates of losses per share improve by 10%

Neuronetics, Inc. Announces New Advancements of NeuroStar Advanced Therapy System

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Neuronetics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

President exercised options to buy US$341k worth of stock.

Neuronetics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Neuronetics, Inc. Launches Innovations to Neurostar Advanced Therapy’s Proprietary Trakstar Platform

Neuronetics: Growth To Capture, But Fairly Priced

Is Neuronetics (NASDAQ:STIM) Using Debt Sensibly?

Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression

Bruce J. Shook Notifies the Board of Directors of Neuronetics, Inc. to Resign from the Board Effective as of October 31, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Neuronetics, Inc. Provides Earnings Guidance for the Quarter Ending September 30, 2022 and for the Year Ending December 31, 2022

Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance

Senior VP notifies of intention to sell stock